← boardnext 2027-05
VXRT
Vaxartdistress 4/10 · elevated risk$0.50+4%today-37% from 52w high
Infectious Disease 1
Lead: COVID-19
Revenue
$39M
Liquidity
$61M
Runway
1.8 yrs
Shares 1y
+6%
Price & events
-24.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.2%
1D
-2.0%
1W
-3.8%
1M
-32.4%
3M
-25.4%
6M
+19.0%
1Y
-27.5%
2Y
-93.9%
5Y
-92.1%
All
Overview
- Market Cap
- $120.99M
- Volume
- 262
- 52 Week Range
- $0.33 – $0.80
- Total Shares
- 241.97M
- Float Shares
- 238.37M
- Short %
- 9.40%
- % Held by Insiders
- 1.33%
- % Held by Institutions
- 0.05%
- RVOL
- 0.00x
- Beta
- 1.09
Pipeline stages · 1 programs
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 | SARS-CoV2, COVID-19 | — | active not recruiting |
| 2026-05-01 | Phase 1 | VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T | Norovirus Infections | 60 | active not recruiting |
Catalyst news & presentations · 9
- early 2027Guided 70%readoutPhase 2COVID-19 oral vaccine · Primary efficacy and safety readout from main cohort of Phase 2b trialSEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- second quarter of 2026readoutPhase 2COVID-19 oral vaccine · 12-month safety data from sentinel cohort of Phase 2b trialSEC 8-K
- 2026-06-22partnershiporal pill COVID-19 vaccine candidate · Modification No. 7 to BARDA Project Agreement reduces total funding to ~$345M and releases ~$29M for trial completion and exploratory analyses.SEC 8-K
- 2026-04-16partnershipVaxart entered purchase agreement with Lincoln Park for up to $25M common stockSEC 8-K
- 2025-11-04partnershiporal COVID-19 vaccine candidate · Exclusive license and collaboration agreement with DynavaxSEC 8-K
- 2025-10-08trial discontinuedoral pill COVID-19 vaccine candidate · BARDA intends to delimit Project Agreement; paused work excluded; follow-up of ~5,000 enrolled participants continues.SEC 8-K
- 2025-08-05trial discontinuedoral pill COVID-19 vaccine candidate · Received stop work order from BARDA; enrollment halted except per-protocol follow-up of already dosed participants.SEC 8-K
- 2025-05-15fda agreementoral COVID-19 vaccine · BARDA approved initiation of dosing in the 10,000-participant portion of ongoing Phase 2b trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $3 (+567% upside) · 3 analysts
- 2025-03-27B. Riley SecuritiesBuy
- 2024-08-15OppenheimerOutperform
Competitors — COVID-19
Recent news
- 2026-07-22Vaxart (VXRT) AGM 2026 Summary - Quartr
- 2026-07-21Form 4 Vaxart Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Form 4 Vaxart Inc For: 21 July By Investing.com - Investing.com Canada
- 2026-07-21Vaxart's vaccine pills can be stored and shipped without refrigeration - Stock Titan
- 2026-07-21Vaxart to Participate in BTIG Biotechnology Conference 2026 - Yahoo! Finance Canada
- 2026-07-20Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now - TradingView
- 2026-07-17Vaxart (Nasdaq: VXRT) sees directors re-elected but executive pay vote fails - Stock Titan
- 2026-07-17Vaxart Announces Results of Annual Meeting of Stockholders - Vaxart Inc.
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.